Thanks to our unique and extensive experience in ophthalmology, Iris Pharma supplies the necessary resources to guide and speed-up new ocular drug discovery through the drug development process. Our focus on the eye creates value for our customers because it enables us to work quickly and accurately, helping to get drugs on the market more quickly. Iris Pharma is the first Contract Research Organization (CRO) to be totally dedicated to ophthalmology, offering a complete range of services to pharmaceutical, biotech and medical device companies worldwide.
CUTTING-EDGE PRECLINICAL STUDIES IN OPHTHALMOLOGY SERVICES
Iris Pharma has a preclinical laboratory totally dedicated to ophthalmology. We offer partial or global outsourcing of animal studies to determine the safety of test articles under laboratory conditions. Our dedicated preclinical department manages animal studies for the development of drugs and devices using a state-of-the-art apparatus in ophthalmology such as a Spectralis®HRA+OCT and a Heidelberg Retina Tonograph 2 (HRT2). We not only perform highly controlled studies to obtain regulatory authorization (registration studies, GLP safety testing), but also propose pilot studies (proof of concept) that correspond to simplified prospective studies.
The applied research department develops new animal models according to the specific requirements of our clients, as well as working to improve existing models. Today, we have experience in studying the efficacy of test products in many ocular pathologies including Age-related Macular Degeneration (AMD) and glaucoma with our 48 different ocular efficacy in vivo models.
Our nonclinical laboratory staff are trained for micro-dissection of ocular samples, surgical administration of ophthalmic drugs and devices (including intravitreal, subconjunctival, sub-Tenon, retrobulbar, periocular, intracamerular, subretinal, intrascleral, and intrastromal administration) and also for surgical implantation (including intravitreal and subconjunctival implants).